Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07746154

Alpha Down EEG Neurofeedback for Alcohol Use Disorder: Feasibility Trial

This pilot study is testing a short brain training program called neurofeedback in adults with alcohol use disorder. Participants will complete three sessions over about one week. The goal is to learn if this approach is easy to complete, well tolerated, and acceptable to participants. We will also explore whether it is associated with changes in alcohol cravings and drinking.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Alcohol use disorder (AUD) is a common condition, and many individuals do not respond fully to existing treatments. Neurofeedback is a non-invasive method that uses real-time electroencephalography (EEG) signals to provide feedback, allowing individuals to learn to modulate their brain activity.

This pilot study will evaluate a brief EEG-based neurofeedback intervention in adults with AUD. Participants will complete three in-person sessions over approximately one week. During each session, EEG sensors are placed on the scalp to measure brain activity, and participants receive real-time feedback based on these signals.

The neurofeedback protocol targets downregulation of alpha-band activity (8-12 Hz). This approach differs from traditional alpha-theta neurofeedback and is intended to target patterns of brain activity related to attention, inhibitory control, and craving.

The primary aim is to assess feasibility, tolerability, and acceptability. Feasibility will be evaluated through recruitment, retention, and session completion. Tolerability will be assessed by monitoring adverse events, and acceptability will be assessed through participant-reported experience.

Exploratory outcomes will include changes in alcohol craving and alcohol use based on self-report measures. These analyses are exploratory and intended to inform future studies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults ages 18-65 Meets DSM-5 criteria for current Alcohol Use Disorder Willing and able to provide informed consent Participants must report alcohol consumption within the past 30 days. Not requiring inpatient withdrawal management at the time of enrollment

Exclusion criteria

History of epilepsy or seizure disorder (excluding uncomplicated alcohol withdrawal seizures) Current psychosis, mania, or acute suicidality, or any psychiatric condition that would impair the ability to provide informed consent or safely participate Acute alcohol intoxication at the time of study visits (as determined by breathalyzer) Pregnancy or breastfeeding Implanted electronic medical devices or metal in the head (excluding dental work), if incompatible with EEG procedures Severe cognitive impairment interfering with informed consent or participation Any medical or psychiatric condition that, in the opinion of the investigators, would make participation unsafe or interfere with study procedures

Treatment and study plan

EEG Neurofeedback

Device

Participants will receive a brief course of EEG-based neurofeedback consisting of three sessions over approximately one week. During each session, scalp electrodes are placed to record brain activity using electroencephalography (EEG). Real-time feedback is provided to guide participants in modulating their brain activity.

The neurofeedback protocol targets downregulation of alpha-band activity (8-12 Hz). Training is delivered using a standardized protocol with real-time visual and/or auditory feedback. Each session lasts approximately 20 minutes, with additional time for setup and brief assessments.

Primary outcomes

  1. Participant retention rate over 1 week

    Time frame: one week

    Proportion of participants who complete all study visits

  2. Proportion of participants experiencing adverse events during neurofeedback sessions over 1 week

    Time frame: One week

    Number and severity of adverse events

  3. Proportion of scheduled neurofeedback sessions completed over 1 week

    Time frame: One week

    Proportion of scheduled neurofeedback sessions completed

Secondary outcomes

  1. Change in alcohol craving (PACS total score) from baseline to Visit 3 (~1 week)

    Time frame: One week

    Alcohol craving will be assessed using the Penn Alcohol Craving Scale (PACS). Change in total PACS score from baseline to the final visit will be analyzed.

  2. Change in alcohol consumption measured by Timeline Follow-Back (TLFB) from baseline (Visit 1) to post-intervention (Visit 3, ~1 week)

    Time frame: One week

    Alcohol consumption will be assessed using the Timeline Follow-Back (TLFB) method. Change in number of standard drinks over the assessment period from baseline to the final visit will be analyzed.

Study contacts

Contact information is provided by the study sponsor or research team.

Naomi Rosenblum

CONTACT

[email protected]

8572054415

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Registry information

Acronym: Neurofeedback

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Aug 4, 2026
Registry last updated
Aug 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.